ArriVent BioPharma (AVBP) News Today $23.27 -0.36 (-1.52%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$23.26 -0.02 (-0.06%) As of 06/13/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVBP Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by California State Teachers Retirement SystemCalifornia State Teachers Retirement System lifted its stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 561.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,649 shares of the company'June 12 at 3:39 AM | marketbeat.comOptimistic Outlook for ArriVent BioPharma, Inc. Amid Promising Developments and Market SupportJune 9, 2025 | tipranks.comWellington Management Group LLP Takes $1.12 Million Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)Wellington Management Group LLP bought a new stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 41,921 shares of the company's stock, valued at apJune 7, 2025 | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives $39.29 Consensus PT from AnalystsJune 6, 2025 | americanbankingnews.comArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading Volume - Still a Buy?ArriVent BioPharma (NASDAQ:AVBP) Sees Unusually-High Trading Volume - Here's WhyJune 4, 2025 | marketbeat.comMillennium Management LLC Reduces Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP)Millennium Management LLC lowered its stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 75.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 52,545 shares of the company's stock after selling 164,085 shares during the period. MilJune 4, 2025 | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of "Buy" by AnalystsShares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven analysts that are currently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation and one has assignedJune 3, 2025 | marketbeat.comBNP Paribas Financial Markets Decreases Stock Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)BNP Paribas Financial Markets cut its position in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 85.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,300 shares of the company's stock after selling 18,665 shares durJune 2, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Up 6.7% - Here's WhyArriVent BioPharma (NASDAQ:AVBP) Trading 6.7% Higher - Here's What HappenedMay 30, 2025 | marketbeat.comInfinitum Asset Management LLC Buys Shares of 1,643,923 ArriVent BioPharma, Inc. (NASDAQ:AVBP)Infinitum Asset Management LLC bought a new stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,643,923 shares of the company's stock, valMay 28, 2025 | marketbeat.comWoodline Partners LP Boosts Stock Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)Woodline Partners LP boosted its holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 20.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 145,797 shares of the company's stock after purchasinMay 27, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Trading Down 4.5% - Time to Sell?ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 4.5% - Here's What HappenedMay 25, 2025 | marketbeat.comRafferty Asset Management LLC Raises Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)Rafferty Asset Management LLC raised its holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 186.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 27,299 shares of the company's stock after buying an additionMay 25, 2025 | marketbeat.comJones Trading Initiates Coverage of ArriVent BioPharma (AVBP) with Buy RecommendationMay 21, 2025 | msn.comSuvretta Capital Management LLC Acquires 400,838 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP)Suvretta Capital Management LLC increased its position in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 21.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,246,000 shares of the company's stock after purchasing an additionMay 19, 2025 | marketbeat.comArriVent BioPharma Reports Q1 2025 Financial Results and Highlights Key AchievementsMay 17, 2025 | msn.comArriVent BioPharma (NASDAQ:AVBP) Announces Earnings Results, Misses Estimates By $1.24 EPSArriVent BioPharma (NASDAQ:AVBP - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($1.24).May 15, 2025 | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Bought by Octagon Capital Advisors LPOctagon Capital Advisors LP grew its holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 4.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,059,387 shares of the company's stock after acquiring an additional 83,000 shareMay 15, 2025 | marketbeat.comIs ArriVent BioPharma (NASDAQ:AVBP) In A Good Position To Deliver On Growth Plans?May 15, 2025 | uk.finance.yahoo.comArriVent BioPharma (NASDAQ:AVBP) Trading Down 6.7% - Here's WhyArriVent BioPharma (NASDAQ:AVBP) Shares Down 6.7% - Should You Sell?May 14, 2025 | marketbeat.comArriVent BioPharma: Promising Clinical Developments and Strategic Advancements Justify Buy RatingMay 12, 2025 | tipranks.comArriVent BioPharma Reports First Quarter 2025 Financial ResultsMay 12, 2025 | globenewswire.comArriVent BioPharma (AVBP) to Release Earnings on WednesdayArriVent BioPharma (NASDAQ:AVBP) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-arrivent-biopharma-inc-stock/)May 9, 2025 | marketbeat.comBarclays PLC Grows Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP)Barclays PLC increased its stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 28.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 53,499 shares of the company's stock after purchasing an additional 11,977 shares during the periodMay 6, 2025 | marketbeat.comInvesco Ltd. Takes Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)Invesco Ltd. purchased a new position in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 15,339 shares of the company's stock, valued at approximately $May 6, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down - Here's WhyArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down - Time to Sell?May 5, 2025 | marketbeat.comNovo Holdings A S Grows Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP)Novo Holdings A S boosted its position in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 1.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,520,627 shares of the company's stock after acquiring an additional 15,3May 3, 2025 | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest UpdateArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 5,360,000 shares, a growth of 31.7% from the March 31st total of 4,070,000 shares. Based on an average trading volume of 203,000 shares, the short-interest ratio is currently 26.4 days. Currently, 27.6% of the shares of the stock are sold short.May 3, 2025 | marketbeat.comArriVent BioPharma Appoints Dr. Merdad Parsey to Board of DirectorsMay 1, 2025 | msn.comArriVent BioPharma appoints new board memberApril 30, 2025 | uk.investing.comArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of DirectorsApril 28, 2025 | globenewswire.comArriVent BioPharma (NASDAQ:AVBP) Trading Up 4.9% - Here's What HappenedArriVent BioPharma (NASDAQ:AVBP) Trading 4.9% Higher - Time to Buy?April 23, 2025 | marketbeat.com41,921 Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Bought by Wellington Management Group LLPWellington Management Group LLP purchased a new stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 41,921 shares of the company's stock, valued at approximately $1,April 15, 2025 | marketbeat.comVanguard Group Inc. Has $37.76 Million Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP)Vanguard Group Inc. raised its holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 5.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,417,291 shares of the company's stock after buying an additional 71,April 15, 2025 | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Buy" by BrokeragesArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) has been given an average recommendation of "Buy" by the six research firms that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the compaApril 15, 2025 | marketbeat.comArriVent Biopharma management to meet with OppenheimerApril 9, 2025 | markets.businessinsider.comArriVent BioPharma (NASDAQ:AVBP) Sets New 52-Week Low - What's Next?ArriVent BioPharma (NASDAQ:AVBP) Hits New 12-Month Low - Time to Sell?April 9, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading Volume - Should You Buy?ArriVent BioPharma (NASDAQ:AVBP) Sees Large Volume Increase - What's Next?April 6, 2025 | marketbeat.comSwiss National Bank Buys Shares of 26,400 ArriVent BioPharma, Inc. (NASDAQ:AVBP)Swiss National Bank purchased a new stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 26,400 shares of the company's stock, valued at approximately $703March 30, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Stock Price Up 2.2% - Here's WhyArriVent BioPharma (NASDAQ:AVBP) Trading 2.2% Higher - Time to Buy?March 29, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% - Time to Sell?ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 4.7% - Should You Sell?March 26, 2025 | marketbeat.comIntech Investment Management LLC Acquires Shares of 14,798 ArriVent BioPharma, Inc. (NASDAQ:AVBP)Intech Investment Management LLC purchased a new stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 14,798 shares of the company's stock, valued at apprMarch 26, 2025 | marketbeat.comBrokers Offer Predictions for AVBP Q1 EarningsArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - B. Riley issued their Q1 2025 earnings per share (EPS) estimates for ArriVent BioPharma in a research note issued on Wednesday, March 19th. B. Riley analyst K. Patel forecasts that the company will post earnings of ($0.70) per share for the qMarch 24, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Raised to Strong-Buy at B. RileyB. Riley raised shares of ArriVent BioPharma to a "strong-buy" rating in a research report on Wednesday.March 22, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up - Still a Buy?ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up - Time to Buy?March 21, 2025 | marketbeat.comLatest ArriVent BioPharma Stock News | NASDAQ:AVBP | BenzingaMarch 21, 2025 | benzinga.comB. Riley Securities Initiates Coverage of ArriVent BioPharma (AVBP) with Buy RecommendationMarch 21, 2025 | msn.comArriVent BioPharma (NASDAQ:AVBP) Now Covered by Analysts at B. RileyB. Riley initiated coverage on shares of ArriVent BioPharma in a research note on Thursday. They set a "buy" rating and a $37.00 target price for the company.March 21, 2025 | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Recommendation of "Buy" from AnalystsShares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) have been assigned a consensus rating of "Buy" from the five ratings firms that are covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year taMarch 21, 2025 | marketbeat.comArriVent Biopharma initiated with a Buy at B. RileyMarch 20, 2025 | markets.businessinsider.com Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address AVBP Media Mentions By Week AVBP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVBP News Sentiment▼1.500.89▲Average Medical News Sentiment AVBP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVBP Articles This Week▼32▲AVBP Articles Average Week Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MoonLake Immunotherapeutics News Today Catalyst Pharmaceuticals News Today Metsera News Today Crinetics Pharmaceuticals News Today Viking Therapeutics News Today MorphoSys News Today Scholar Rock News Today Immunovant News Today HUTCHMED News Today Apellis Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVBP) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVBP Stock Free AVBP Stock Alerts